- Future Students
- DVM degree program
- Graduate Programs
- Request information
- Contacts, Map, and Directions
- Current Students
- Faculty & Staff
Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
|Title||Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.|
|Publication Type||Journal Article|
|Year of Publication||2002|
|Authors||Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL|
|Journal||Clinical cancer research : an official journal of the American Association for Cancer Research|
|Date Published||2002 Jul|
|Keywords||Adenocarcinoma, Adult, Aged, Antibodies, Neoplasm, Cancer Vaccines, Chorionic Gonadotropin, Colorectal Neoplasms, Diphtheria Toxin, Female, Humans, Immunotherapy, Male, Middle Aged, Recombinant Fusion Proteins, Safety, Survival Rate, Vaccination|
PURPOSE: Human chorionic gonadotropin (hCG) is produced by colorectalcancers and may play a role in its progression. The clinical and immunological effects of a synthetic vaccine targeting beta-hCG composed of the COOH terminal peptide of beta-hCG (CTP37) conjugated to diphtheria toxoid (DT) was investigated in patients with metastatic colorectal cancer.
EXPERIMENTAL DESIGN: Seventy-seven patients from 12 centers were randomly divided into two vaccine dose groups. CTP37-DT was formulated in an emulsion and administered i.m. on days 0, 28, and 70. Patients were evaluated for toxicity, overall survival, and antibody response to hCG and to DT.
RESULTS: Immunizations were well tolerated with no patients requiring cessation of the injections. Anti-hCG antibody was detected in 56 of the 77 patients treated. Significant differences in antibody response and survival were not observed between the two dose groups. An intention-to-treat analysis of all vaccinated patients showed a median survival of 34 weeks. Patients who developed anti-hCG antibody levels higher than or equal to the median value exhibited a median survival of 45 weeks compared with 24 weeks for patients who developed anti-hCG antibody levels lower than the median (P = 0.0002). In contrast, no significant difference was observed when comparing survival based upon the level of DT antibody that developed (P = 0.80).
CONCLUSIONS: Vaccination with CTP37-DT induced anti-hCG antibodies in most patients with advanced colorectal cancer. Anti-hCG antibody induction was associated with longer overall survival. CTP37-DT has an excellent safety profile and warrants further study in patients with colorectal cancer.
|Alternate Journal||Clin. Cancer Res.|